Construction and Engineering

Legence - CL

Stifel Nicolaus Maintains Buy Rating on Legence Corp. with $101 Target Price

Legence - CL released FY2026 Q1 earnings on May 14 Pre-Market (EST), actual revenue USD 1.038 B (forecast USD 930.48 M), actual EPS USD 0.13 (forecast USD 0.2107)

Legence Q1 Revenue Doubles, Raises 2026 Full-Year Guidance to $4.3 Billion

Legence - CL to Release FY2026 Q1 Earnings on May 14 Pre-Market EST, Forecast Revenue USD 930.48 M, EPS USD 0.2107

GLJ Research gives Legence Corp a buy rating

Legence Shareholders Plan Secondary Offering of 11 Million Class A Ordinary Shares

Legence Corp. Reports Mixed Q4 Earnings and Raises Sales Guidance

Legence - CL released FY2025 Annual Earnings on March 27 Pre-Market (EST), Actual Revenue: USD 2.55 B (Forecast: USD 2.433 B), Actual EPS: USD -0.5691 (Forecast: USD -0.307)

Legence - CL released FY2025 Q4 earnings on March 27 Pre-Market (EST), actual revenue USD 737.64 M (forecast USD 619.31 M), actual EPS USD -0.55 (forecast USD 0.0381)

Legence - CL to Release FY2025 Q4 Earnings on March 27, 2026 Pre-Market EST, Forecast Revenue USD 619.31 M, EPS USD 0.0381

Blackstone EMA III and Legence Parent ML sold shares of Legence Corp.

Underwriters Exercise Over-allotment Option for Legence Corp.

Legence signs the 12th amendment to credit agreement with Jefferies Finance

Legence Corp. Completes Acquisition of The Bowers Group for $325 Million

Blackstone and Legence Parent Selling Legence Corp. Stocks

Legence Corp. Acquires IMD

Tigress Financial Analyst Upgrades Legence Corp. to Buy

Jefferies Upgrades Legence Stock Rating and Raises Price Target

Legence - CL released FY2025 9 Months Earnings on November 14 Pre-Market EST, actual revenue USD 1.813 B, actual EPS USD -0.0098

Legence - CL released FY2025 Q3 earnings on November 14 Pre-Market (EST), actual revenue USD 708.01 M (forecast USD 638.93 M), actual EPS USD -0.0183 (forecast USD 0.0587)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

Micware

BiomX

MetaVia

MicroAlgo

Quantum Cyber NV

Brian Brophy from Stifel Nicolaus has maintained a Buy rating on Legence Corp. Class A (LGN) with a price target of $101.00. Brophy has an average return of 64.7% and an 82.31% success rate. Additionally, BMO Capital's Devin Dodge also rated it a Buy, while Barclays maintained a Hold rating.

Tip Ranks

Stifel Financial

Comfort Systems USA

EMCOR Grp

Bank of Montreal

Barclays

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Legence Corp. Class A (LGN) Receives a Rating Update from a Top Analyst

DOCS

LWLG

CRVS

ENVX

DXYZ

CSIQ

PDFS

Doximity(DOCS) fell 23%, with a trading turnover 452.3 Million USD, and a year-to-date fell 59.3%. Lightwave Logic(LWLG) fell 18.03%, with a trading turnover 256.9 Million USD, and a year-to-date rose 360.8%. Corvus Pharma(CRVS) fell 13.79%, with a trading turnover 54.8 Million USD, and a year-to-date rose 77.3%.

Top Gainers&Losers

Doximity

Lightwave Logic

Corvus Pharma

Enovix

Destiny Tech100

Prestige Brands

Canadian Solar

PDF Solutions

Top 10 US Stock Losers (5.14)

Earnings Watch

Legence - CL | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.038 B

Legence Corp.'s average stock price target has increased from $81.12 to $83.62, indicating a potential downside of approximately 16% based on the May 13 closing price. The consensus rating remains a 'Buy' from 18 analysts, with 17 recommending 'Buy' and 1 'Hold'.

TradingView

Legence Corp. Stock 12‑Month Price Target Raised to $83.62, Implies 16% Downside

Legence (NASDAQ:LGN) reported Q1 2026 revenues exceeding $1 billion, more than doubling year-over-year, driven by organic growth and the acquisition of Bowers. The company raised its full-year revenue guidance to $4.1-$4.3 billion and EBITDA guidance to $470-$490 million. Adjusted EBITDA grew by 132% year-over-year, with a record backlog of $5.4 billion, indicating strong future demand, particularly in data centers and technology sectors. Legence continues to focus on strategic growth through acquisitions in mission-critical building systems.

Fidelity

Legence Q1 2026 Earnings Call Transcript

Legence Corp. (NASDAQ: LGN) shares fell 5.20% to $94.80 despite reporting Q1 revenue of $1.03 billion, a 105% year-over-year increase, and raising its FY26 revenue outlook to $4.10-$4.30 billion. The company also provided Q2 guidance of $1.05-$1.10 billion, exceeding estimates. However, earnings per share of 13 cents missed the consensus of 21 cents. CEO Jeff Sprau highlighted strong demand and project execution, supported by a record backlog of $5.38 billion.

Legence - CL(LGN.US)

Legence Corp. Class A (LGN) Receives a Rating Update from a Top Analyst

Top 10 US Stock Losers (5.14)

Legence - CL | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.038 B

Legence Corp. Stock 12‑Month Price Target Raised to $83.62, Implies 16% Downside

Legence Q1 2026 Earnings Call Transcript

Legence Stock Retreats Despite Triple-Digit Revenue Growth And Raised Outlook